LC determination of glimepiride and its related impurities

Journal of Pharmaceutical and Biomedical Analysis

Volumn 39, Issue 5, 2005, Pages 928-943

  Khan, Mubeen Ahmad ^a   Sinha, Sukumar ^a   Vartak, Santosh ^a   Bhartiya, Atul ^a   Kumar, Shankar ^a  

^a Glenmark Pharmaceuticals Limited   (India)

Author keywords

API; Characterization; Glimepiride; HPLC; Related impurities

Indexed keywords

1 [[2 [2 (3 ETHYL 4 METHYL 2 OXO 3 PYRROLINE 1 CARBOXAMIDO)ETHYL]PHENYL] SULFONYL] 3 (4 METHYLCYCLOHEXYL)UREA; 1 [[3 [2 (3 ETHYL 4 METHYL 2 OXO 3 PYRROLINE 1 CARBOXAMIDO)ETHYL]PHENYL] SULFONYL] 3 (4 METHYLCYCLOHEXYL)UREA; 1 [[4 [2 (3 ETHYL 4 METHYL 2 OXO 3 PYRROLINE 1 CARBOXAMIDO)ETHYL]PHENYL] SULFONYL] 3 (4 METHYLCYCLOHEXYL)UREA; ACETONITRILE; GLIMEPIRIDE; N [4 [2 (3 ETHYL 4 METHYL 2 OXO 3 PYRROLINE 1 CARBOXAMIDO)ETHYL]]BENZENE SULFONAMIDE; N [[4 [2 (3 ETHYL 4 METHYL 2 OXO 3 PYRROLINE 1 CARBOXAMIDO)ETHYL]] BENZENESULFONYL]ETHYLCARBAMATE; PHOSPHATE; SULFONAMIDE; TETRAHYDROFURAN; UNCLASSIFIED DRUG; URETHAN;

ACCURACY; ANALYTIC METHOD; ARTICLE; CIS ISOMER; DRUG DEGRADATION; DRUG IMPURITY; DRUG STRUCTURE; FLOW RATE; OBSERVER VARIATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SEPARATION TECHNIQUE; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; DRUG STABILITY; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; ISOMERISM; MAGNETIC RESONANCE SPECTROSCOPY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SOLUTIONS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SULFONYLUREA COMPOUNDS;

EID: 26644466095     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2005.06.007     Document Type: Article

References (19)

1. R. Weyer, V. Hitzel, K. Geisen, G. Regitz (Hoechst AG), Sulfonylureas, Process for their Preparation, Pharmaceutical Compositions Containing Them and Their Use, EP 031058.
2. W. Kramer, G. Muller, and F. Girbig Biochim. Biophys. Acta 119 1994 278 290
3. E. Draeger Diab. Res. Clin. Pract. 28 Suppl. 1 1995 139 146
4. J. Trous, and J. Cascaner Drugs Fut. 17 9 1992 774
5. H. Kim, K.Y. Chang, C.H. Park, M.S. Jang, J.A. Lee, H.J. Lee, and K.R. Lee Chromatographia 60 1-2 2004 93 98
6. L.C. Lu, Y.F. Pu, X.H. Jiang, J. Zhou, and J.Y. Yang Yaowu Fenxi Zazhi 22 3 2002 211 214
7. C. Tang, X.H. Zhang, and M. Huang Yaowu Fenxi Zazhi 23 4 2003 271 273
8. Y. Jin, H. Chen, S.F. Gu, L.X. Hu, and F.D. Zeng Yaowu Fenxi Zazhi 23 4 2003 263 264
9. H.H. Maurer, C. Kratzsch, T. Kraemer, F.T. Peters, and A.A. Weber J. Chromatogr. Biomed. Appl. 526 2 1990 497 505
10. K.H. Lehr, and P. Damm J. Chromatogr. 526 2 1990 497 505
11. Y. Song, L.P. Niu, D.F. Wang, Y.P. Hu, and D.Y. Hou J. Sep. Sci. 26 17 2003 1595 1597
12. Y.R. Song, D.F. Wang, L.P. Niu, Y.P. Hu, Y.P. Yang, and D.Y. Hou Fenxi Huaxue 32 4 2004 435 438
13. J. Wei, W.X. Wang, L.J. Gao, Z.R. Sun, J.Z. Ma, and J.W. Xie Yaowu Fenxi Zazhi 23 3 2003 207 209
14. P. Kovarikova, J. Klimes, J. Dohnal, and L. Tisovska J. Pharm. Biomed. Anal. 36 1 2004 205 209
15. Official Monographs, USP 28, pp. 3239-3240.
16. PHARMAEUROPA, vol. 16, no. 3, July 2004, pp. 435-436.
17. ICH Guidelines Q3A (R) Impurities in New Drug Substances, February 2002.
18. ICH Guidelines Q3B (R) Impurities in New Drug Products, February 2002.
19. ICH Guidelines Q1A (R2), Stability Testing of New Drug Substances and Products, February 2003.